Payment overview · 2025
General Payments
$487.58
20 reported records · 10 companies
Healthcare provider profile · identity verified
Peter Steven Stack, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PLANO, TX · NPI 1275649725
Verified facts
What the public records show
CMS Open Payments records show Peter Steven Stack, M.D. received $487.58 in general payments during 2025 across 20 reported records.
Exact Sciences Corporation accounted for 30.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $147.99 | 30.4% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $70.37 | 14.4% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $58.01 | 11.9% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $50.98 | 10.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $42.14 | 8.6% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $41.67 | 8.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.21 | 4.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.89 | 4.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.55 | 3.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.77 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $487.58 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $58.01 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $54.06 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $50.98 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $41.67 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $35.59 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $26.63 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.21 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.21 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.21 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.89 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.51 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.51 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
74 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 321 | 84 |
| Levothyroxine Sodium | Levothyroxine Sodium | 198 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 185 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 153 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 152 | 43 |
| Losartan Potassium | Losartan Potassium | 141 | 43 |
| Lisinopril | Lisinopril | 136 | 40 |
| Gabapentin | Gabapentin | 123 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 114 | 37 |
| Simvastatin | Simvastatin | 112 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 102 | 30 |
| Trazodone Hcl | Trazodone Hcl | 90 | 25 |
| Celecoxib | Celecoxib | 85 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 85 | 23 |
| Metformin Hcl | Metformin Hcl | 80 | 23 |
| Eliquis | Apixaban | 74 | 21 |
| Alprazolam | Alprazolam | 72 | 24 |
| Furosemide | Furosemide | 64 | 23 |
| Sertraline Hcl | Sertraline Hcl | 59 | 14 |
| Allopurinol | Allopurinol | 58 | 14 |
| Synthroid | Levothyroxine Sodium | 58 | 16 |
| Methylprednisolone | Methylprednisolone | 53 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | 21 |
| Azithromycin | Azithromycin | 51 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 50 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 50 | 14 |
| Irbesartan | Irbesartan | 49 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 48 | 18 |
| Jardiance | Empagliflozin | 47 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 16 |
| Carvedilol | Carvedilol | 44 | suppressed |
| Ezetimibe | Ezetimibe | 44 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 44 | 13 |
| Spironolactone | Spironolactone | 44 | 15 |
| Diazepam | Diazepam | 43 | 11 |
| Prednisone | Prednisone | 43 | 21 |
| Omeprazole | Omeprazole | 42 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | 14 |
| Finasteride | Finasteride | 39 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 33 |
| Montelukast Sodium | Montelukast Sodium | 38 | 14 |
| Alendronate Sodium | Alendronate Sodium | 37 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 11 |
| Potassium Chloride | Potassium Chloride | 37 | 12 |
| Tramadol Hcl | Tramadol Hcl | 37 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Famotidine | Famotidine | 32 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 29 | suppressed |
| Lorazepam | Lorazepam | 29 | 11 |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Meloxicam | Meloxicam | 26 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 25 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 22 |
| Testosterone | Testosterone | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 18 | 14 |
| Ozempic | Semaglutide | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | 13 |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | 12 |
| Atenolol | Atenolol | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $487.58 · 20 records | Exact Sciences Corporation | ABRYSVO, AREXVY, COMIRNATY, Cologuard Collection Kit, EVENITY, LEQVIO, Leqembi, OTEZLA, PREVNAR 20, REPATHA, SHINGRIX, TRELEGY ELLIPTA, TZIELD, Veozah, Wegovy, ZORYVE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error